Industry News (Cancer Vaccines)

Malignant Melanoma Cancer Vaccine Trial Reaches Full Enrollment -

Published in Vaccine Weekly, October 11th, 1999

Progenics Pharmaceuticals, Inc., Tarrytown, New York, announced that Progenics and Bristol-Myers Squibb have reached the targeted full enrollment in the pivotal Phase III clinical trial of GMK, a therapeutic cancer vaccine.

GMK is being developed for the treatment of malignant melanoma, a highly fatal form of skin cancer.

The study, the largest ever performed in melanoma, has enrolled over 850 patients at approximately 300 medical centers throughout the United States. The trial will close to further enrollment on October 15, 1999, and will have exceeded the targeted number of patients. The trial is being conducted by the National Cancer...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (1999-10-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry